Bicycle Therapeutics PLC (BCYC) News

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its...

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on November 1, 2024, the Compensation Committee of the company’s Board of Directors...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy...

Form 8-K - Current report

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of...

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Company to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities